These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 2818657)
1. Factor B activation products in patients with systemic lupus erythematosus. A marker of severe disease activity. Kerr LD; Adelsberg BR; Schulman P; Spiera H Arthritis Rheum; 1989 Nov; 32(11):1406-13. PubMed ID: 2818657 [TBL] [Abstract][Full Text] [Related]
2. Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity. Manzi S; Rairie JE; Carpenter AB; Kelly RH; Jagarlapudi SP; Sereika SM; Medsger TA; Ramsey-Goldman R Arthritis Rheum; 1996 Jul; 39(7):1178-88. PubMed ID: 8670328 [TBL] [Abstract][Full Text] [Related]
3. Activation of the alternative complement pathway accompanies disease flares in systemic lupus erythematosus during pregnancy. Buyon JP; Tamerius J; Ordorica S; Young B; Abramson SB Arthritis Rheum; 1992 Jan; 35(1):55-61. PubMed ID: 1731815 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of alternative pathway and factor B haemolytic activities in patients with systemic lupus erythematosus: correlations with the alternative pathway regulatory proteins. Aguado MT; Perrin LH; Ramirez R; Miescher PA; Lambert PH Clin Exp Immunol; 1980 Dec; 42(3):495-505. PubMed ID: 6163579 [TBL] [Abstract][Full Text] [Related]
5. Increased amounts of C4-containing immune complexes and inefficient activation of C3 and the terminal complement pathway in a patient with homozygous C2 deficiency and systemic lupus erythematosus. Garred P; Mollnes TE; Thorsteinsson L; Erlendsson K; Steinsson K Scand J Immunol; 1990 Jan; 31(1):59-64. PubMed ID: 2300790 [TBL] [Abstract][Full Text] [Related]
6. Correlation of the activation of the fourth component of complement (C4) with disease activity in systemic lupus erythematosus. Senaldi G; Makinde VA; Vergani D; Isenberg DA Ann Rheum Dis; 1988 Nov; 47(11):913-7. PubMed ID: 3264693 [TBL] [Abstract][Full Text] [Related]
7. Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum. Mayes JT; Schreiber RD; Cooper NR J Clin Invest; 1984 Jan; 73(1):160-70. PubMed ID: 6418767 [TBL] [Abstract][Full Text] [Related]
8. Relative importance of C3b inactivator and beta 1H globulin in the modulation of the properdin amplification loop in systemic lupus erythematosus. Whaley K; Schur PH; Ruddy S Clin Exp Immunol; 1979 Jun; 36(3):408-14. PubMed ID: 114347 [TBL] [Abstract][Full Text] [Related]
9. Activation of factor B of the alternative pathway of complement. Assessment by rocket immunoelectrophoresis. Kajdacsy-Balla A; Doi EM; Bagasra O Am J Clin Pathol; 1987 Jul; 88(1):66-73. PubMed ID: 3649166 [TBL] [Abstract][Full Text] [Related]
10. Complement split product C3d as an indicator of disease activity in systemic lupus erythematosus. Röther E; Lang B; Coldewey R; Hartung K; Peter HH Clin Rheumatol; 1993 Mar; 12(1):31-5. PubMed ID: 8467609 [TBL] [Abstract][Full Text] [Related]
11. A novel ELISA for the assessment of classical pathway of complement activation in vivo by measurement of C4-C3 complexes. Zwirner J; Dobos G; Götze O J Immunol Methods; 1995 Oct; 186(1):55-63. PubMed ID: 7561148 [TBL] [Abstract][Full Text] [Related]
12. Utilization of complement testing in clinical medicine. Abdul-Aziz K; Faizal AA Saudi Med J; 2006 Nov; 27(11):1775-7. PubMed ID: 17106567 [No Abstract] [Full Text] [Related]
13. Complement activation before, during and after cardiopulmonary bypass. Bonser RS; Dave JR; John L; Gademsetty MK; Carter PG; Davies E; Taylor P; Gaya H; Lennox SC; Vergani D Eur J Cardiothorac Surg; 1990; 4(6):291-6. PubMed ID: 2361017 [TBL] [Abstract][Full Text] [Related]
14. Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus Erythematosus. Ramsey-Goldman R; Alexander RV; Massarotti EM; Wallace DJ; Narain S; Arriens C; Collins CE; Saxena A; Putterman C; Kalunian KC; O'Malley T; Dervieux T; Weinstein A Arthritis Rheumatol; 2020 Jan; 72(1):78-88. PubMed ID: 31469249 [TBL] [Abstract][Full Text] [Related]
15. C4a anaphylatoxin levels as an indicator of disease activity in systemic lupus erythematosus. Wild G; Watkins J; Ward AM; Hughes P; Hume A; Rowell NR Clin Exp Immunol; 1990 May; 80(2):167-70. PubMed ID: 2357842 [TBL] [Abstract][Full Text] [Related]
16. [Components of the classical complement pathway in systemic lupus erythematosus]. Maillet F; Goetz J; Hauptmann G; Clauvel JP; Mery JP; Kahn MF; Kazatchkine M Presse Med; 1987 Mar; 16(8):378-82. PubMed ID: 2950498 [TBL] [Abstract][Full Text] [Related]
17. Neutrophil chemotaxis and serum chemotactic activity in systemic lupus erythematosus. Alvarez I; Vazquez JJ; Fontan G; Gil A; Barbado J; Ojeda JA Scand J Rheumatol; 1978; 7(2):69-74. PubMed ID: 705269 [TBL] [Abstract][Full Text] [Related]
18. Urine neopterin as a parameter of disease activity in patients with systemic lupus erythematosus: comparisons with serum sIL-2R and antibodies to dsDNA, erythrocyte sedimentation rate, and plasma C3, C4, and C3 degradation products. Lim KL; Jones AC; Brown NS; Powell RJ Ann Rheum Dis; 1993 Jun; 52(6):429-35. PubMed ID: 8323394 [TBL] [Abstract][Full Text] [Related]
20. Complement Alternative Pathway׳s Activation in Patients With Lupus Nephritis. Song D; Guo WY; Wang FM; Li YZ; Song Y; Yu F; Zhao MH Am J Med Sci; 2017 Mar; 353(3):247-257. PubMed ID: 28262211 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]